<DOC>
	<DOCNO>NCT01981707</DOCNO>
	<brief_summary>Until today current diagnostic tool exists identify early objective response patient castration-resistant prostate cancer treat abiraterone acetate enzalutamide . According Prostate Cancer Working Group , investigator wait 12 week first evaluation . To know soon treatment effective decisive oncologist , even palliative situation second effect ca n't impose patient . In post-docetaxel , F-choline PET-CT could use assess response new therapy . Moreover , investigator suppose assess early stage objective therapeutic response , 6 week treatment , order avoid unnecessarily expansive treatment . The aim study ass possible determine early ( 6 week treatment ) F-choline PET-CT could predict response abiraterone acetate enzalutamide post-docetaxel .</brief_summary>
	<brief_title>F-choline PET Early Response Assessment Castration Resistant Prostatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Age &gt; 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less Histologically cytologically confirm adenocarcinoma prostate cancer without neuroendocrine component ( component minority neuroendocrine ) small cell , neuroendocrine cell small minority component prostate underwent surgical medical castration Disease progression docetaxelbased chemotherapy serum testosterone level 50 ng per deciliter le ( ≤2.0 nmol per liter ) Biologic criterion : platelet ≥ 100 000/μl , Creatinine &lt; 1.5 x upper limit creatinine clearance ≥ 60 ml / min , Serum potassium ≥ 3.5 mmol / l , Bilirubin &lt; 1.5 x upper limit normal ( ULN ) hemoglobin ≥ 9.0 g / dl without transfusion . abnormal aminotransferase level ( level aspartate aminotransferase alanine aminotransferase ≥2.5 time upper level normal range ; patient know liver metastasis level aspartate aminotransferase alanine aminotransferase ≤5 time upper level normal range eligible participate previous therapy ketoconazole serious coexist nonmalignant disease : active symptomatic viral hepatitis chronic liver disease , uncontrolled hypertension , history pituitary adrenal dysfunction , clinically significant heart disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>castration-resistant prostate cancer</keyword>
	<keyword>abiraterone acetate</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>choline pet</keyword>
</DOC>